Impact of FDA black box advisory on antipsychotic medication use

Archives of Internal Medicine

Volumn 170, Issue 1, 2010, Pages 96-103

  Dorsey, E Ray ^a   Rabbani, Atonu ^b,c   Gallagher, Sarah A ^b   Conti, Rena M ^b,c   Alexander, G Caleb ^b,c,d,e  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT;

ARTICLE; DEMENTIA; DRUG INDICATION; DRUG INFORMATION; DRUG USE; FOOD AND DRUG ADMINISTRATION; HUMAN; OFF LABEL DRUG USE; PRESCRIPTION; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DEMENTIA; DRUG LABELING; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; REGRESSION ANALYSIS; RISK MANAGEMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 74549137304     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.456     Document Type: Article

References (39)

1. Risperdal: full US prescribing information. http://www.risperdal.com/ risperdal/prescribing.html. Accessed August 15, 2009.
2. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ. 2005;172(13):1703-1711.
3. Food and Drug Administration. Risperdal (risperidone). April 2003. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm153478.htm. Accessed August 15, 2009.
4. Food and Drug Administration. Zyprexa (olanzapine). March 2004. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm166542.htm. Accessed August 15, 2009.
5. Food and Drug Administration. Atypical antipsychotic drugs. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm150688.htm. Accessed August 15, 2009.
6. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775-786.
7. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627-632.
8. Food and Drug Administration. Antipsychotics: conventional and atypical. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm110212.htm. Accessed August 15, 2009.
9. Morgan OW, Griffiths C, Majeed A. Interrupted time-series analysis of regulations to reduce paracetamol (acetaminophen) poisoning. PLoS Med. 2007;4(4):e105.
10. Jacoby JL, Fulton J, Cesta M, Heller M. After the black box warning: dramatic changes in ED use of droperidol [letter]. Am J Emerg Med. 2005;23(2):196.
11. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of Cisapride: impact of Food and Drug Administration regulatory action. JAMA. 2000;284(23):3036-3039.
12. Cheung A, Sacks D, Dewa CS, Pong J, Levitt A. Pediatric prescribing practices and the FDA black-box warning on antidepressants. J Dev Behav Pediatr. 2008;29(3):213-215.
13. Bhatia SK, Rezac AJ, Vitiello B, Sitorius MA, Buehler BA, Kratochvil CJ. Antidepressant prescribing practices for the treatment of children and adolescents. J Child Adolesc Psychopharmacol. 2008;18(1):70-80.
14. Nemeroff CB, Kalali A, Keller MB, et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry. 2007;64(4):466-472.
15. Valuck RJ, Libby AM, Orton HD, Morrato EH, Allen R, Baldessarini RJ. Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry. 2007;164(8):1198-1205.
16. Busch SH, Barry CL. Pediatric antidepressant use after the black-box warning. Health Aff (Millwood). 2009;28(3):724-733.
17. Wood R, Botting B, Dunnell K. Trends in conceptions before and after the 1995 pill scare. Popul Trends. 1997;89(89):5-12.
18. Special Report: the publication of new evidence and effect on physician prescribing behaviors. Technol Eval Cent Asses Program Exec Summ. 2004;19(11):1-3.
19. Valiyeva E, Herrmann N, Rochon PA, Gill SS, Anderson GM. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ. 2008;179(5):438-446.
20. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among officebased physicians. Arch Intern Med. 2006;166(9):1021-1026.
21. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291(1):47-53.
22. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 2003;41(1):56-61.
23. Zell ER, McCaig LF, Kupronis BA, Besser RE, Schuchat A. A comparison of the National Disease and Therapeutic Index and the National Ambulatory Medical Care Survey to evaluate antibiotic usage. http://www.amstat.org/sections/SRMS/ proceedings/papers/2000-143.pdf. Accessed October 20, 2009.
24. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299-309.
25. Ramsay CR, Matowe L, Grilli R, Grimshaw JM, Thomas RE. Interrupted time series designs in health technology assessment: lessons from two systematic reviews of behavior change strategies. Int J Technol Assess Health Care. 2003;19(4):613-623.
26. Cameron AC, Trivedi PK. Microeconometrics Methods and Applications. New York, NY: Cambridge University Press; 2005.
27. Shumway RH, Stoffer DS. Time Series Analysis and Its Applications With Examples. 2nd ed. New York, NY: Springer; May 2006.
28. Walton SM, Schumock GT, Lee KV, Alexander GC, Meltzer D, Stafford RS. Prioritizing future research on off-label prescribing: results of a quantitative evaluation Pharmacotherapy. 2008;28(12):1443-1452.
29. Joinpoint Regression Program, latest release version 3.3. April 2008. http://srab.cancer.gov/joinpoint/. Accessed June 17, 2009.
30. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates [published correction appears in Stat Med. 2001 Feb 28;20(4):655]. Stat Med. 2000;19(3):335-351.
31. Huntzinger A. FDA warns against off-label use of antipsychotic drugs. Am Fam Physician. June 1, 2005;71:2205.
32. Agency for Healthcare Research and Quality. Efficacy and comparative effectiveness of off-label use of atypical antipsychotics. Rockville, MD: Agency for Healthcare Research and Quality; 2007. AHRQ Publication No. 07-EHC003-EF.
33. Schneider LS, Tariot PN, Dagerman KS, et al; CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355(15):1525-1538.
34. Dorsey ER, Thompson JP, Noyes K, Dick AW, Holloway RG, Schwid SR. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis. Neurology. 2007;68(18):1524-1528.
35. Libby AM, Brent DA, Morrato EH, Orton HD, Allen R, Valuck RJ. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry. 2007;164(6):884-891.
36. Katz LY, Kozyrskyj AL, Prior HJ, Enns MW, Cox BJ, Sareen J. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. CMAJ. 2008;178(8):1005-1011.
37. Lagnado L. Prescription abuse seen in US nursing homes - powerful antipsychotics used to subdue elderly; huge Medicaid expense. Wall Street Journal. December 4, 2007:A1.
38. Tarkan L. Doctors say medication is overused in dementia. New York Times. June 24, 2008:F6.
39. Katz LY. Concerns about health care warnings and their impact on prescribing behavior. CMAJ. 2008;179(5):405-406.